

Effective Date: July 21, 2025

## **TEST CHANGE**

SC5b-9

3017902, SC5B-9

Specimen Requirements:			
Patient Preparation:			
Collect:	Pink (K2EDTA), <u>t</u> ∓an (K2EDTA), <u>r</u> Royal blue (K2EDTA), or <u>l</u> Lavender (EDTA).		
Specimen Preparation:	Separate plasma within 2 hours (1 hour is preferable) by centrifugation. ~2700 rpm (1300 100 g) for 10 minutes.  Transfer plasma (minimum 0.5 mL) to an ARUP standard transport tube and freeze immediately.		
Transport Temperature:	CRITICAL FROZEN. Separate specimens must be submitted when multiple tests are ordered.		
Unacceptable Conditions:	Nonfrozen specimens. Specimens exposed to repeated freeze/thaw cycles. Grossly hemolyzed, lipemic, and icteric specimens. Serum samples. Heparinized and lithium samples.		
Remarks:			
Stability:	Ambient: Unacceptable; Refrigerated: Unacceptable; Frozen: 30 days		
Methodology:	Quantitative Enzyme-Linked Immunosorbent Assay (ELISA)		
Performed:	Sun, Wed		
Reported:	2-12 days		
Note:			
CPT Codes:	86160		
New York DOH Approval Status:	This test is New York DOH approved.		

Elevated soluble C5b-9 (SC5b-9) levels indicate recent or ongoing activation of the complement system, while normal or reduced levels suggest no excessive activation. High SC5b-9 concentrations are associated with transplant-associated thrombotic microangiopathy (TA-TMA), a complication of hematopoietic stem cell transplants. Increased SC5b-9 may also occur in various conditions involving primary or secondary complement activation, such as immune-complex disease, infection, atypical hemolytic uremic syndrome, and C3 glomerulopathies. Due to a low specificity for SC5b-9 testing, results should be interpreted in combination with other clinical and laboratory evidence of disease activity. Plasma SC5b-9 levels may be used to monitor the efficacy of complement inhibitor drugs, as elevated levels suggest insufficient complement blockage to



effectively prevent the formation of the terminal attack complex.

## Reference Interval:

Test Number	Components	Reference Interval
	C5b9 Soluble Terminal Complement Complex	Less than or equal to 260 ng/mL

Effective Date: July 21, 2025